Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A [1 ]
Lisak, L [1 ]
Dutt, D [1 ]
Dean, L [1 ]
Fantroy, L [1 ]
Syed, E [1 ]
Gezer, S [1 ]
Hsu, WT [1 ]
Goldberg, C [1 ]
Loew, J [1 ]
Venugopal, P [1 ]
机构：
[1] Rush Univ, MDS Ctr, Chicago, IL 60612 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4830
引用
收藏
页码：273B / 273B
页数：1
相关论文
共 50 条
  • [21] Pregnancy in patients with myelodysplastic syndromes (MDS)
    Volpicelli, P.
    Latagliata, R.
    Breccia, M.
    Carmosino, I.
    Stefanizzi, C.
    Napoleone, L.
    Vozella, F.
    Levi, A.
    Natalino, E.
    Alimena, G.
    LEUKEMIA RESEARCH, 2008, 32 (10) : 1605 - 1607
  • [22] A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
    Wei, Wei
    Zhou, Fan
    Zhang, Yizi
    Guo, Lieping
    Shi, Haotian
    Hou, Jian
    LEUKEMIA RESEARCH, 2012, 36 (06) : 715 - 719
  • [23] Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis
    Martinelli, G
    Mingrone, W
    Alietti, A
    Ferrucci, F
    Cocorocchio, E
    Peccatori, F
    Cinieri, S
    Corsini, C
    Zucca, E
    Bertolini, F
    ANNALS OF ONCOLOGY, 2000, 11 : 54 - 54
  • [24] Arsenic trioxide (Trisenox®) with/without thalidomide in patients with myelodysplastic syndromes (MDS) produces hematologic improvement (HI).
    Raza, A
    Lisak, L
    Billmeier, J
    Akbar, S
    Washeed, K
    Mumtaz, M
    Reddy, P
    Galili, N
    BLOOD, 2004, 104 (11) : 261B - 262B
  • [25] Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, L
    Andrews, C
    Little, L
    Muzammil, M
    Alvi, S
    Mazzoran, L
    Zorat, F
    Akber, A
    Ekbal, M
    Razvi, S
    Venugopal, P
    BLOOD, 1999, 94 (10) : 661A - 661A
  • [26] Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
    Kasprzak, Annika
    Nachtkamp, Kathrin
    Gattermann, Norbert
    Germing, Ulrich
    CANCERS, 2022, 14 (08)
  • [27] INTENSIVE CHEMOTHERAPY FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    BERNSTEIN, SH
    BRUNETTO, VL
    DAVEY, FR
    MAYER, RJ
    WURSTERHILL, D
    SCHIFFER, CA
    BLOOMFIELD, CD
    BLOOD, 1993, 82 (10) : A196 - A196
  • [28] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [29] The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
    Zorat, F
    Shetty, V
    Dutt, D
    Lisak, L
    Nascimben, F
    Allampallam, K
    Dar, S
    York, A
    Gezer, S
    Venugopal, P
    Raza, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) : 881 - 894
  • [30] Delayed responses to thalidomide in patients with myelodysplastic syndromes.
    Lisak, LA
    Little, L
    Dean, L
    Ekbal, M
    duRandt, M
    Hussain, M
    Kaistha, V
    Raza, A
    BLOOD, 2000, 96 (11) : 261B - 261B
12345